Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical Technologies's earnings before interest and taxes (EBIT) for the
three
months ended in Apr. 2026 was $-36.80 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2026 was $-123.77 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Kestra Medical Technologies's annualizedROC % for the quarter that ended in Apr. 2026 was -156.26%.
Kestra Medical Technologies's annualizedROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -246.00%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Kestra Medical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -10.69%.
Kestra Medical Technologies (NAS:KMTS) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Kestra Medical Technologies's annualizedROC % for the quarter that ended in Apr. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a EBIT of $-123.77 Mil as of Apr. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kestra Medical Technologies.
Is Kestra Medical Technologies' EBIT too high?
Kestra Medical Technologies' current EBIT is $-123.77 Mil. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' EBIT compare to ATRC and STAA?
Kestra Medical Technologies' EBIT of $-123.77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kestra Medical Technologies. Kestra Medical Technologies's current EBIT is $-123.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current EBIT of $-123.77 Mil. The current EBIT is $-123.77 Mil. Kestra Medical Technologies' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current EBIT is $-123.77 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
